Home › Results From the AMBITION Study of First-Line Treatment With Letairis...
 

Keywords :   


Results From the AMBITION Study of First-Line Treatment With Letairis...

2015-08-27 01:47:44| Biotech - Topix.net

Gilead Sciences, Inc. today announced detailed results from the AMBITION study . In AMBITION, conducted in collaboration with GlaxoSmithKline , combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm .

Tags: with results study treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.12South Western Railway to be renationalised by Labour
03.12Labelexpo South China 2024 features latest industry trends
03.12PPG Earns Two Awards During CARES 2024 Automotive Forums in U.S., Europe
03.12Filtrex 2025 to be Held in March
03.12Nu-Maber Italy adds dual ThermoFlexX Catena-E 80 units
03.12TEKLYNX assists with label compliance
03.12Megnajet supporting Arrow Systems\' growing digital portfolio
03.12WEG Achieves Gold Certification in EcoVadis for Second Consecutive Year
More »